Built-in data integrity controls, guided operation and extended test durations for inhaler testing.
17 November 2026; Nottingham, UK: Copley Scientific has launched the new Breath Actuation Controller BAC 200iX®, comprehensively enhancing a core inhaler testing ancillary to deliver greater test flexibility for delivered dose uniformity (DDU) testing and aerodynamic particle size distribution (ASPD) measurement for orally inhaled and nasal drug products (OINDPs).
Combining guided test set-up with precise control of sampling duration and actuation timing, the BAC 200iX supports consistent, controlled testing across a broad range of applications. Built-in method management, secure user access, audit trails and reporting further strengthen traceability and support 21 CFR Part 11 and GMP requirements.
The BAC 200iX is also the latest addition to Copley’s connected inhaler testing range, offering optional connectivity with Inhalytix®+ for centralised method and user management, and synchronisation of supported testing information.
“Our priority with the BAC 200iX was to make routine inhaler testing more straightforward while strengthening control over how tests are set up, executed and recorded,” said Paul Martin, Head of Business Development. “We’ve focused on practical enhancements that help laboratories maintain consistent procedures and meet the demands of regulated testing.”
Supporting the flow control requirements for DDU testing and APSD measurement, for MDIs, soft mist inhalers (SMIs) and nebulisers, the BAC 200iX introduces several key enhancements:
- Expanded operational range: extended sampling durations of up to 50 minutes and a lower flow-rate capability broaden the range of workflows that can be performed using a single controller.
- Simplified test set-up: clear on-screen instructions guide analysts through test configuration, while saved methods and automated in situ leak testing help reduce manual setup tasks and support consistent procedures.
- Strengthened control and traceability at the instrument: the ability to manage methods, user permissions and test records directly on the instrument helps laboratories maintain consistent procedures, improve accountability and support data integrity requirements.
- QR code equipment identification: an optional QR Code Scanner enables the BAC 200iX to identify compatible QR-coded Copley equipment and record its details against the test method and test record, strengthening equipment traceability.
- Automatic pump control: automatic switching of Copley 7-series vacuum pumps reduces the risk of tests starting without vacuum, while avoiding unnecessary pump runtime.
- Inhalytix+ connectivity: defined methods and users can be synchronised between the BAC 200iX and Inhalytix+, with supported operating information and test reports captured centrally for more consistent, traceable data management.
‘With the BAC 200iX joining the recently launched Critical Flow Controller TPK 200iX®, laboratories now have a choice of next-generation flow controllers suited to different testing requirements’, concludes Paul. ‘Importantly, both instruments offer enhanced control and traceability as standalone solutions, with the option to extend these capabilities through Inhalytix®+ for centralised management across the wider laboratory workflow.’
For more information about the BAC 200iX® and its capabilities, visit https://www.copleyscientific.com/inhaler-testing/ancillaries/flow-controllers/bac-200ix/ or contact the Copley team.

The new Copley Breath Actuation Controller BAC 200iX® (left) and BAC 200iX®-R (right) for controlled sampling duration and actuation timing for Delivered Dose Uniformity (DDU) testing and Aerodynamic Particle Size Distribution (APSD) measurement.
About Copley Scientific
Copley Scientific is widely recognised as the world’s leading provider of inhaler testing solutions and is a major supplier of testing systems for other pharmaceutical dosage forms. The company also supplies equipment for detergent testing.
Copley’s inhaler testing portfolio supports all types of orally inhaled and nasal drug products, including metered-dose inhalers, dry powder inhalers, nebulisers and nasal products. Its solutions span delivered dose uniformity and aerodynamic particle size distribution measurement, combining specialist testing equipment with software, automation, accessories and support services to help laboratories build controlled, consistent and increasingly connected testing workflows.
It’s wider pharmaceutical testing product range also includes testers for tablets (dissolution, disintegration, friability and hardness), capsules, powders, suppositories, semisolids and transdermals.
Used from R&D through to QC, Copley’s product and solutions portfolio is supported by a full validation and aftersales service. Copley works in partnership with specialist distributors, extending localised support across the world. This network provides expert help and training to every customer. www.copleyscientific.com
For further information
Press information/Company contact:
Rosanna Kelly, Marketing Manager
Copley Scientific Limited
Colwick Quays Business Park, Road No. 2, Nottingham, NG4 2JY, UK
Tel: +44 (0)115 961 6229
mediarelations@copleyscientific.co.uk